Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald C Goff

Showing results (21-30 of 207) with videos related to

Pageof 21
Sort By:
Harvard Review of Psychiatry|July 11, 2024
Why Do Veterans Not Respond as Well as Civilians to Trauma-Focused Therapies for PTSD?Max Kitaj, Donald C Goff
Biological Psychiatry|June 28, 2023
Dose Finding for d-Serine Enhancement of Plasticity in SchizophreniaKatlyn Nemani, Donald C Goff
The Journal of Clinical Psychiatry|November 25, 2003
Polypharmacy in schizophrenia: a fuzzy conceptOliver Freudenreich, Donald C Goff
The International Journal of Neuropsychopharmacology|May 13, 2004
Focus on polypharmacy in schizophrenia: does anyone truly benefit?Donald C Goff, Oliver Freudenreich
The American Journal of Psychiatry|July 5, 2011
Antipsychotic polypharmacy: are two ever better than one?Donald C Goff, Lisa Dixon
The Journal of Clinical Psychiatry|August 8, 2008
Varenicline treatment for smokers with schizophrenia: a case seriesA Eden Evins, Donald C Goff
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2015
Cannabinoids and Schizophrenia: Risks and Therapeutic PotentialMarc W Manseau, Donald C Goff
The Journal of Clinical Psychiatry|August 10, 2007
Integrating general health care in private community psychiatry practiceDonald C Goff, John W Newcomer
Biological Psychiatry|September 25, 2016
Is Pupillary Response a Biomarker for Effort and Defeatist Attitudes in Patients With Schizophrenia?Erica D Diminich, Donald C Goff
The American Journal of Psychiatry|March 5, 2020
Does Early Intervention Improve the Long-Term Course of Schizophrenia?Donald C Goff, Chenxiang Li, Lorna Thorpe
Pageof 21

Showing results (21-30 of 207) with videos related to

Sort By:
Pageof 21
Harvard Review of Psychiatry|July 11, 2024
Why Do Veterans Not Respond as Well as Civilians to Trauma-Focused Therapies for PTSD?Max Kitaj, Donald C Goff
Biological Psychiatry|June 28, 2023
Dose Finding for d-Serine Enhancement of Plasticity in SchizophreniaKatlyn Nemani, Donald C Goff
The Journal of Clinical Psychiatry|November 25, 2003
Polypharmacy in schizophrenia: a fuzzy conceptOliver Freudenreich, Donald C Goff
The International Journal of Neuropsychopharmacology|May 13, 2004
Focus on polypharmacy in schizophrenia: does anyone truly benefit?Donald C Goff, Oliver Freudenreich
The American Journal of Psychiatry|July 5, 2011
Antipsychotic polypharmacy: are two ever better than one?Donald C Goff, Lisa Dixon
The Journal of Clinical Psychiatry|August 8, 2008
Varenicline treatment for smokers with schizophrenia: a case seriesA Eden Evins, Donald C Goff
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 28, 2015
Cannabinoids and Schizophrenia: Risks and Therapeutic PotentialMarc W Manseau, Donald C Goff
The Journal of Clinical Psychiatry|August 10, 2007
Integrating general health care in private community psychiatry practiceDonald C Goff, John W Newcomer
Biological Psychiatry|September 25, 2016
Is Pupillary Response a Biomarker for Effort and Defeatist Attitudes in Patients With Schizophrenia?Erica D Diminich, Donald C Goff
The American Journal of Psychiatry|March 5, 2020
Does Early Intervention Improve the Long-Term Course of Schizophrenia?Donald C Goff, Chenxiang Li, Lorna Thorpe
Pageof 21